School of Pharmacy, Shenyang Pharmaceutical University, Wenhua Road 103, P.O. Box 42, Shenyang, Liaoning Province 110016, PR China.
Biomaterials. 2013 Dec;34(37):9602-14. doi: 10.1016/j.biomaterials.2013.08.032. Epub 2013 Sep 7.
Pluronics have been demonstrated as excellent multidrug resistance (MDR) reversal agent in the form of unimers rather than micelles. However, the effective intracellular delivery of Pluronic(®) unimers to MDR cancer cells still remains a big challenge. To address this issue, a mixed micellar system based mainly on the pH-sensitive copolymer of poly (L-histidine)-poly (D,L-lactide)-polyethyleneglycol-poly (D,L-lactide)-poly (L-histidine) (PHis-PLA-PEG-PLA-PHis) and Pluronic(®) F127, some of which was conjugated with folate, was constructed to intracellularly deliver the unimers of Pluronic(®) P85 to MDR cells. The folate-mediated endosomal pH-sensitive mixed micelles (pHendoSM-P85/f) were prepared by a thin-film hydration method, by which Pluronic(®) P85 unimers and doxorubicin (DOX) were incoporated into the mixed micelles. The incorporation of Pluronic(®) P85 unimers was investigated by the surface tension test. The results indicated that the Pluronic(®) P85 unimers probably first inserted into the binary mixed micelles and then formed a triple-component mixed micelles with Pluronic(®) F127 and PHis-PLA-PEG-PLA-PHis as the loading content increased. Further analyzed with flow cytometry, confocal laser scanning microscopy (CLSM) and MTT assay, the micelles with inserted Pluronic(®) P85 unimers demonstrated much more cellular uptake and higher cytotoxicity against MDR cells than the triple-component mixed micelles and plain Pluronic(®) micelles. The enhanced MDR reversal effect was attributed to the successful intracellular delivery of Pluronic(®) P85 unimers to the MDR cells, which was confirmed by the subcellular colocalization of Pluronic(®) P85 unimers with mitochondria, the decreased ATP energy and mitochondrial membrane potential (MP) in the MCF-7/ADR cells. The pHendoSM-P85/f/DOX also demonstrated more dramatic antitumor efficiency and remarkable reduction of ATP energy in the MDR cells in tumors than the control formulations. The intracellular delivery of Pluronic(®) P85 unimers to the MDR cells based on the targeted and endosomal pH triggerd release mixed micelles has been demonstrated as a promising approach to reverse MDR.
普朗尼克(Pluronic)以单体形式而非胶束形式已被证明是一种出色的多药耐药(MDR)逆转剂。然而,将普朗尼克(Pluronic)单体有效递送至 MDR 癌细胞内仍然是一个巨大的挑战。为了解决这个问题,构建了一种基于聚(L-组氨酸)-聚(D,L-丙交酯)-聚乙二醇-聚(D,L-丙交酯)-聚(L-组氨酸)(PHis-PLA-PEG-PLA-PHis)和普朗尼克(Pluronic)®F127 的混合胶束系统,其中一些与叶酸偶联,用于将普朗尼克(Pluronic)®P85 的单体递送至 MDR 细胞内。通过薄膜水化法制备了叶酸介导的内体 pH 敏感混合胶束(pHendoSM-P85/f),其中将普朗尼克(Pluronic)®P85 单体和阿霉素(DOX)掺入混合胶束中。通过表面张力测试研究了普朗尼克(Pluronic)®P85 单体的掺入情况。结果表明,普朗尼克(Pluronic)®P85 单体可能首先插入到二元混合胶束中,然后随着载药量的增加,与普朗尼克(Pluronic)®F127 和 PHis-PLA-PEG-PLA-PHis 形成三元混合胶束。进一步通过流式细胞术、共聚焦激光扫描显微镜(CLSM)和 MTT 测定进行分析,与三元混合胶束和普通普朗尼克(Pluronic)胶束相比,插入普朗尼克(Pluronic)®P85 单体的胶束表现出更高的细胞摄取率和对 MDR 细胞的更高细胞毒性。增强的 MDR 逆转作用归因于普朗尼克(Pluronic)®P85 单体向 MDR 细胞的成功递送至 MDR 细胞,这通过普朗尼克(Pluronic)®P85 单体与线粒体的亚细胞共定位、 MCF-7/ADR 细胞中 ATP 能量和线粒体膜电位(MP)的降低得到证实。pHendoSM-P85/f/DOX 在肿瘤中的 MDR 细胞中也表现出更显著的抗肿瘤效率和显著降低的 ATP 能量。基于靶向和内体 pH 触发释放的混合胶束将普朗尼克(Pluronic)®P85 单体递送至 MDR 细胞内已被证明是逆转 MDR 的一种有前途的方法。